Skip to main content
Premium Trial:

Request an Annual Quote

Immucor Gains CE-IVD Mark for Array-Based Human Erythrocyte Antigen Test


By Justin Petrone

Immucor last week said it has received a CE-IVD Mark for its Human Erythrocyte Antigen BeadChip for molecular immunohematology in vitro diagnostic purposes.

The multiplex test performs extended typing of 32 red blood cell antigens, predicting the phenotypes of the Rh, Kell, Duffy, Kidd, MNS, Lutheran, Dombrock, Landsteiner-Wiener, Diego, Colton, and Scianna blood group systems.

While the assay has been available for research use in Europe, the company believes its certification as an in vitro diagnostic will allow more users in blood banks, clinical laboratories, and blood donor centers to adopt the technology.

Gioacchino De Chirico, president and CEO of the Norcross, Ga.-based firm, said that European regulatory clearance is a "significant commercial milestone" for Immucor, which has run 200,000 HEA tests on the system to date. "We view Europe as a key market to drive continued adoption of molecular methods in the blood bank," De Chirico said in a statement.

Immucor has already received CE Mark approval for its Human Platelet Antigen assay for use in platelet genotyping, as well as its instrument, the Array Imaging System.

The molecular immunohematology test provider gained its array-based technology platform in 2008 via its $117 million acquisition of Warren, NJ-based platform developer BioArray Solutions (BAN 3/18/2008). Immucor is currently preparing a fully automated, next-generation system for a research market debut next year (BAN 4/10/2010).

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.